Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.79 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714016 | 0.90 | PTGDR2 (0.78) | PTGDR2MGLL | |
| SCHEMBL1713751 | 0.89 | PTGDR2 (1.00) | PTGDR2MGLLKDM4EALDH1A1TDP1 | |
| SCHEMBL1714395 | 0.85 | PTGDR2 (0.93) | PTGDR2MGLLKDM4EALDH1A1TDP1 | |
| SCHEMBL1714524 | 0.82 | PTGDR2 (0.80) | PTGDR2MGLLPKMKDM4EALDH1A1 | |
| SCHEMBL1714764 | 0.80 | PTGDR2 (0.80) | PTGDR2MGLLKDM4EALDH1A1 | |
| SCHEMBL13800153 | 0.79 | PTGDR2 (0.72) | PTGDR2MGLL | |
| SCHEMBL1714166 | 0.79 | PTGDR2 (1.00) | PTGDR2MGLLKDM4EALDH1A1 | |
| SCHEMBL1714457 | 0.78 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL1714817 | 0.77 | PTGDR2 (0.77) | PTGDR2KDM4EALDH1A1TDP1 | |
| SCHEMBL4117458 | 0.77 | PTGDR2 (0.75) | PTGDR2MGLLKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | claimed |
| EP-1817282-B1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | claimed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | claimed |
| EP-1817282-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | claimed |
| US-8524715-B2 | Phenoxyacetic acid derivatives useful for treating respiratory diseases | ASTRAZENECA AB (SE) | 2013-09-03 | — | — | US | disclosed |
| EP-1817282-B1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-07-20 | — | — | EP | disclosed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | PAOX, PCCA, PAH | PTGDR2 236/4885MGLL 1505/4885PLA2G1B 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.